Loading...

TELO TELOMIR PHARMACEUTICALS INC Product Launches 8-K Filing

TLMR

TL

TELOMIR PHARMACEUTICALS INC

(TELO)

2024 8-K

FDA Clearance Announcement

Merger Completion

Compliance Update

IND Submission Update

Shareholder Approvals

Breast Cancer Breakthrough

Research Breakthrough

Nasdaq Compliance Notice

Study Results Announced

Executive Compensation Update

Favorable Safety Results

New Cancer Treatment

Director Resignation

Leukemia Treatment Update

Telomir-1 Breakthrough

New Cancer Research

Cancer Drug Progress

Cancer Treatment Breakthrough

Cancer Research Update

New Drug Insights

New Cancer Data

Stock Sale Complete

New Therapy Insights

Product Expansion

Product Expansion

Equity Offerings

Product Expansion

Product Expansion

Product Expansion

Product Expansion

Strategic Alliances

Product Expansion

Management Changes

Equity Offerings

New Product Launches

Product Expansion

Cancer Drug Results

Breakthrough Announcement

Silver Ion Breakthrough

Oxidative Stress Reduction

Breakthrough Results

Lifespan Restoration

Copper-Binding Drug

Accounting Firm Change

Diabetes Treatment Breakthr...

Management Changes

Age Reversal Study

Management Appointment

External Links:

Telomir Pharmaceuticals confirmed that its lead compound, Telomir-1, has strong copper-binding capabilities, making it a promising treatment for Wilson's disease and other copper-related conditions, with plans for clinical trials starting in 2026.

AI Assistant

TELOMIR PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.